J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
METRO-BIBF: Phase II, randomised, placebo controlled, multicentre, trial of low dose (metronomic) cyclophosphamide (MCy) with or without nintedanib in relapsed ovarian cancer (ROC).
Marcia Hall,Hakim-Moulay Debhi,Shibani Nicum,Rosemary Lord,Susana Banerjee,Andrew R Clamp,Rachel Lilleywhite,Rosalind Glasspool,A Feeney,Allan Hackshaw,Jonathan A. Ledermann +10 more
TL;DR: Oral MCy is well tolerated, avoids IV CT and has been shown to have clinician-friendly properties, similar to other oral chemotherapy agents.
Journal ArticleDOI
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Rebecca C. Arend,Bradley J. Monk,Thomas J. Herzog,Kathleen N. Moore,Ronnie Shapira-Frommer,Jonathan A. Ledermann,Krishnansu S. Tewari,Angeles Alvarez Secord,Tamar Rachmilewitz Minei,Laurence S. Freedman,Austin Miller,Shifra Fain Shmueli,Michal Lavi,Richard T. Penson +13 more
TL;DR: In this paper, the results from a preplanned interim analysis of a phase III, double blind, randomized controlled study of ofranergene obadenovec (VB-111), a targeted anti-cancer gene therapy, in combination with paclitaxel in patients with platinum resistant ovarian cancer (PROC).
Journal ArticleDOI
Antiangiogenic Agents in Cancer Therapy
TL;DR: The book, with its comprehensive review of antiangiogenic agents, will appeal most to scientists and clinicians directly involved in tumour vasculature research and is recommended to any researcher, clinical or scientific, who is about to embark on studies in this very important area.
Journal ArticleDOI
Abstracts of the 12th International Charité Mayo Conference on “Global Perspectives and Future Directions in Women’s Cancer”
Frederik Marmé,Ursula A. Matulonis,Jørn Herrstedt,Amit M. Oza,Sven Mahner,Andrés Redondo,Dominique L. Berton,Jonathan S. Berek,Charlotte Aaquist Haslund,Antonio González-Martín,Stéphanie Becourt,Anna V. Tinker,Jonathan A. Ledermann,Benedict B. Benigno,Gabriel Lindahl,Nicoletta Colombo,Izabela A. Malinowska,Bradley J. Monk,Mansoor Raza Mirza +18 more
TL;DR: The 12th International Charité Mayo Conference as discussed by the authors was held in Berlin, Germany from 26-29 April, 2023, with the theme of "GLOBAL PERSPECTIVES and Future Directions".
Journal ArticleDOI
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer
Sudha Sundar,Andy Nordin,Jo Morrison,Nicholas J Wood,Sadaf Ghaem-Maghami,Joaquin J. Nieto,Andrew N. Phillips,J. N. Butler,Kevin Burton,R Gornall,Stephen Dobbs,Rosalind Glasspool,Richard Peevor,Jonathan A. Ledermann,Iain A. McNeish,Nithya Ratnavelu,Timothy J. Duncan,Jonathan A Frost,Kenneth Lim,Agnieszka Michael,Elly Brockbank,Ketankumar Gajjar,Alexandra Taylor,R L Bowen,A. Andreou,Raji Ganesan,Shibani Nicum,Richard J. Edmondson,Richard Clayton,Janos Balega,Phil Rolland,Hilary Maxwell,Christina Fotopoulou +32 more
TL;DR: The National Ovarian Cancer Audit feasibility pilot (OCAFP) showed that approximately 1 in 4 women with advanced stage ovarian cancer (greater than Stage 2) do not receive any anti-cancer treatment and only 51% will receive both surgery and chemotherapy in England as discussed by the authors .